Oncology Clinical care Precision medicine Screening and monitoring

PAM50 Test Sharpens the View on Recurrent Prostate Cancer

First biomarker-driven randomized trial in non-metastatic prostate cancer underscores the diagnostic potential of molecular assays

10/07/2025 Discussion 1 min read

article Full Article subjectSummary summarizeNotecard

Share

0

BALANCE trial evaluates PAM50 in recurrent prostate cancer.
295 men participated, assigned to apalutamide or placebo.
Luminal B tumors showed 72 percent success rate with apalutamide.
Non-luminal B tumors showed minimal difference in results.
First validation of a predictive biomarker for non-metastatic prostate cancer.
Helps integrate biomarkers into clinical workflows.
PAM50 test available via Veracyte’s Decipher GRID.